Naoumidi Tatiana L, Kounis George A, Astyrakakis Nikolaos I, Tsatsaronis Dimitrios N, Pallikaris Ioannis G
University of Crete Medical School, Vardinoyannion Eye Institute of Crete, Heraklion, Greece.
J Cataract Refract Surg. 2006 May;32(5):732-41. doi: 10.1016/j.jcrs.2006.01.062.
To evaluate the safety, efficacy, predictability, and stability of conductive keratoplasty (CK) for the treatment of hyperopic astigmatism.
University of Crete Medical School, Vardinoyannion Eye Institute of Crete, Heraklion, Greece.
In this prospective nonrandomized noncontrolled single-center study, 47 eyes of 34 patients (15 women and 19 men) were treated for hyperopic astigmatism (up to + 3.50 diopters [D]) with a Refractec ViewPoint CK system and followed for 24 months +/- 0.6 (SD). The treatment consisted of 4 to 36 spots applied to the periphery of the cornea. Mean age was 48.5 years +/- 9.7 years, range 25 to 68 years. All the treated eyes were analyzed for safety, efficacy, predictability, and stability.
The mean patient age was 48.5 +/- 9.7 years (range 25 to 68 years). Preoperatively, the mean manifest refraction spherical equivalent (MRSE) was +2.11 +/- 0.88 D (range -0.50 to + 4.13 D); at 12 months, it was -0.52 +/- 0.73 D and at 24 months, -0.50 +/- 0.77 D. At 24 months, the mean MRSE was within +/-0.50 D in 61% of eyes, within +/-1.00 D in 83%, and within +/-2.00 D in all eyes. At 24 months, the uncorrected visual acuity was 20/20 or better in 37% of eyes and 20/40 or better in 97%. By the end of the follow-up period, no eye had lost > or =2 Snellen lines or had an induced cylinder > or =1.50 D.
Conductive keratoplasty for low hyperopic astigmatism was a safe, effective, and stable procedure. Nomogram adjustments and careful patient selection should contribute to higher levels of predictability when treating hyperopic astigmatism.
评估传导性角膜成形术（CK）治疗远视散光的安全性、有效性、可预测性和稳定性。
希腊伊拉克利翁市克里特大学医学院瓦迪诺扬尼翁眼科研究所。
在这项前瞻性非随机非对照单中心研究中，使用Refractec ViewPoint CK系统对34例患者（15名女性和19名男性）的47只眼睛进行远视散光（最高+3.50屈光度[D]）治疗，并随访24个月±0.6（标准差）。治疗包括在角膜周边施加4至36个光斑。平均年龄为48.5岁±9.7岁，范围为25至68岁。对所有接受治疗的眼睛进行安全性、有效性、可预测性和稳定性分析。
患者平均年龄为48.5±9.7岁（范围25至68岁）。术前，平均显验光球镜等效度（MRSE）为+2.11±0.88 D（范围-0.50至+4.13 D）；12个月时为-0.52±0.73 D，24个月时为-0.50±0.77 D。24个月时，61%的眼睛平均MRSE在±0.50 D以内，83%在±1.00 D以内，所有眼睛均在±2.00 D以内。24个月时，37%的眼睛未矫正视力达到20/20或更好，97%达到20/40或更好。到随访期结束时，没有眼睛视力下降≥2行或诱导柱镜度≥1.50 D。
传导性角膜成形术治疗低度远视散光是一种安全、有效且稳定的手术。在治疗远视散光时，通过调整列线图和仔细选择患者应能提高可预测性。
